CompletedPhase 2

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

United States261 participantsStarted 2016-09

Plain-language summary

The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes).

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HSV-2 seropositive * A minimum of 1 year of reported history of genital herpes with recurrences. Exclusion Criteria: * History of receiving an investigational HSV vaccine * Chronic illness for which a subject's immune system is suspected to be impaired or altered, such as cancer, autoimmune conditions, or diabetes * Pregnant or breastfeeding

What they're measuring

Lesion recurrences

Timeframe: Up to Day 450

Trial details

NCT IDNCT02837575

SponsorVical

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-04

View on ClinicalTrials.gov More Herpes Genitalis trials